

Clinical trials of ticlopidine

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs control			
Knudsen-A , 1985 n=24/19 follow-up: 3m	ticlopidine 500mg/d versus placebo	patients with AMI	Parallel groups double blind

More details and results :

- antiplatelets drug for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q390>

References

Knudsen-A, 1985:

Knudsen JB, Kjeller E, Skagen K, Gormsen J The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Thromb Haemost 1985;53:332-6 [[3901391](#)]

2 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs placebo			
Ellis , 1986 n=100/103 follow-up: 6 months	Ticlopidine 500 mg/j versus Placebo	AOMI stade II	Parallel groups double blind
Hurlow , 1980 n=30/30 follow-up:	Ticlopidine : 100 -500 mg / jour pendant 2 mois. versus Placebo	Donnes non disponibles	Parallel groups double blind
Berglund , 1985 n=21/17 follow-up: 2m	ticlopidine 500 mg daily versus placebo	middle-aged men with stable incapacitating angina pectoris	parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
Krause , 1980 n=19/19 follow-up:	Ticlopidine : 500 mg pendant 4 mois versus Placebo	Donnes non disponibles	Parallel groups double blind
Katsumara , 1982 n=93/100 follow-up: 6 semaines	Ticlopidine 500 mg/j versus Placebo	patients with ischemic ulcers due to chronic arterial occlusion	Parallel groups double blind
Birmingham-A , 1979 <i>unpublished</i> n=20/8 follow-up: 2 months	-	-	Parallel groups
Aukland , 1982 n=33/32 follow-up: 1 y	Ticlopidine 500 mg/j versus Placebo	men with atherosclerotic intermittent claudication and haemorheological abnormalities	Parallel groups double blind
London diabetes , 1983 <i>unpublished</i> n=38/40 follow-up: 12 months	-	-	Parallel groups
Stiegler , 1984 n=57/57 follow-up:	Ticlopidine 500 mg/j versus Placebo	AOMI stade II	Parallel groups double blind
TIMAD , 1984 n=220/215 follow-up: 32m	-	-	Parallel groups
BTRS , 1992 n=49/51 follow-up: 48 months	ticlopidine 500mg/d versus placebo	insulin-treated diabetics with background retinopathy	Parallel groups double blind
Nyberg , 1984 n=12/11 follow-up: 12 months	ticlopidine 500mg daily versus placebo	insulin dependent diabetes complicated by nephropathy	Parallel groups double blind
Cloarec , 1986 n=66/66 follow-up: 1 y	Ticlopidine 500 mg/j versus Placebo	AOMI stade non precis	Parallel groups double blind
Arcan , 1988 n=83/86 follow-up: 6 months	Ticlopidine 500 mg/j versus Placebo	patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II)	Parallel groups double blind
Balsano , 1989 n=76/75 follow-up: 21 months	Ticlopidine 500 mg/j versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
STIMS , 1990 n=346/341 follow-up: 5.6 y	Ticlopidine 500 mg/j versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
EMATAP , 1993 n=304/311 follow-up:	Ticlopidine 500 mg/j versus Placebo	AOMI stade non precis	Parallel groups double blind

More details and results :

- antiplatelets drug for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q220>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with CAD at <http://www.trialresultscenter.org/go-Q276>

References

Ellis, 1986:

DJ Ellis, BR Kamm. Treatment of intermittent claudication with Ticlopidine. Institute of Clinical Medicine, Syntex Research. Palo Alto, CA 94304, USA. Modifier — Effacer — pdf

Hurlow, 1980:

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [[3911481](#)]

Krause, 1980:

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

Katsumara, 1982:

Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A Angiology 1982 Jun;33:357-67 [[7046521](#)]

Birmingham-A, 1979:

unpublished

Pollock A, Wright AD Guildford: Sanofi Winthrop, 1979:(Sanofi internal report 105602-0010)

Auckland, 1982:

Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. Aukland A, Hurlow RA, George AJ, Stuart J J Clin Pathol 1982 Jul;35:740-3 [7047575]

London diabetes, 1983:

unpublished

Oakley NW, Dormandy JA, Flute PT. Guildford: Sanofi Winthrop, 1983:(Internal report 105602-0019.)

Stiegler, 1984:

H Stiegler, H Hess, A Mietaschk, H-J, Trampisch and Ingrisich. DMW 1984, 109:1240-1243.

TIMAD, 1984:

Mirouze J Agents Actions 1984;15(suppl):230-58

BTRS, 1992:

Ophthalmologica 1992;204:4-12 [1579337]

Nyberg, 1984:

Nyberg G, Larsson O, Westberg NG, Aurell M, Jagenburg R, Blohm G Clin Nephrol 1984;21:184-7 [6705280]

Cloarec, 1986:

Cloarec M et al Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs Thrombosis Research 1986 suppl VI abstr 316

Arcan, 1988:

Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E Angiology 1988 Sep;39:802-11 [3048155]

Balsano, 1989:

Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P J Lab Clin Med 1989 Jul;114:84-91 [2661700]

STIMS, 1990:

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al J Intern Med 1990 May;227:301-8 [2187948]

EMATAP, 1993:

J Blanchard, LO Carrerars, M Kindermans and the EMATAP group. Results of EMATAP: a dooble-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev fr Hematol(1993)35:523-528.

3 stable angina

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
Berglund , 1985 n=21/17 follow-up: 2m	ticlopidine 500 mg daily versus placebo	middle-aged men with stable incapacitating angina pectoris	parallel groups double blind

More details and results :

- antithrombotics for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q33>

References

Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [[3911481](#)]

4 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs control			
STAI , 1990 n=314/338 follow-up: 6m	ticlopidine 250 mg b.i.d versus untreated control	patients with unstable angina <=48hrs from the pain onset	single blind
Knudsen-A , 1985 n=24/19 follow-up: 3m	ticlopidine 500mg/d versus placebo	patients with AMI	Parallel groups double blind
ticlopidine vs placebo			
Florida UA unpublished n=12/12 follow-up: 14d	-	-	

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>
- antiplatelets drug for acute coronary syndrome in STEMI patients at <http://www.trialresultscenter.org/go-Q564>

References

STAI, 1990:

Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. *Circulation* 1990;82:17-26 [2194694]

Scrutinio D, Lagioia R, Rizzon P Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. *Eur Heart J* 1991;12 Suppl G:27-9 [1806376]

Knudsen-A, 1985:

Knudsen JB, Kjeller E, Skagen K, Gormsen J The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. *Thromb Haemost* 1985;53:332-6 [3901391]

Florida UA, 0:

unpublished

Mehta JL Unit de Pharmacologie Clinique, 1987. (Unit de Pharmacologie Clinique unpublished report)

5 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
Ticlopidine vs placebo			
Lasierra , 1982 n=40/40	Ticlopidine versus placebo	-	double-blind
Walker , 1974 <i>unpublished</i> n=31/33	ticlopidine versus placebo	-	double-blind
McKenna-II , 1983 n=29/29 follow-up: 2 weeks	Ticlopidine versus placebo	Elective orthopaedic surgery	
Lyon-II , 3000 n=20/20 follow-up: 3 weeks	Ticlopidine versus placebo	Elective orthopaedic surgery	
Gardecki , 3000 n=48/46 follow-up: 2 weeks	Ticlopidine versus placebo	Elective orthopaedic surgery	
McKenna-II , 1983 <i>unpublished</i> n=27/26 follow-up:	Ticlopidine versus placebo	high risk (post CVA) medical patients	Parallel groups double-blind

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antiplatelets drug for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q186>
- antiplatelets drug for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q461>
- antiplatelets drug for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q462>
- antiplatelets drug for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q463>
- antiplatelets drug for thrombosis prevention in elective orthopedic surgery at <http://www.trialresultscenter.org/go-Q464>

References

Lasierra, 1982:

Lasierra J, Arevalo A, Vilades E, Hebrero J, Espinosa H, Yanguela J, et al. Effect of ticlopidin on the risk of thromboembolic disease in the pistoperation. Haemostasis 1982;12:104.

Walker, 1974:

unpublished

Walker MG. Assessment of effect of ticlopidine on intcidence of deep vein thrombosiu in patients undergoing major surgery Guildford: Sanofi Winthrop, 1983. (Sanofi intemal report 001.6.245.)

McKenna-II, 1983:

McKenna R, Galante J, Molony B, Kamm B. Failure of ticlopidine hydrochloride to prevent DVT in orthopedic patients Blood 1983;62(suppl I):304A

Lyon-II, 3000:

Gardecki, 3000:

McKenna-II , 1983:

unpublished

Graham A. A trial of tcopdne hydrochloride for the prevnon of deep vein thrombosis in high risk (post CVA) medical patients Guildford: Sanofi Winthrop, 1983. (Sanofi intemal report 1983. 001.6.188.)

6 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs placebo			
Birmingham-A , 1979 <i>unpublished</i> n=20/8 follow-up: 2 months	-	-	Parallel groups
London diabetes , 1983 <i>unpublished</i> n=38/40 follow-up: 12 months	-	-	Parallel groups
TIMAD , 1984 n=220/215 follow-up: 32m	-	-	Parallel groups
BTRS , 1992 n=49/51 follow-up: 48 months	ticlopidine 500mg/d versus placebo	insulin-treated diabetics with background retinopathy	Parallel groups double blind
Nyberg , 1984 n=12/11 follow-up: 12 months	ticlopidine 500mg daily versus placebo	insulin dependent diabetes complicated by nephropathy	Parallel groups double blind

∞ More details and results :

- antiplatelets drug for diabetes type 2 in patients without cardiovascular disease at <http://www.trialresultscenter.org/go-Q221>
- antiplatelets drug for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q362>

References

Birmingham-A, 1979:

unpublished

Pollock A, Wright AD Guildford: Sanofi Winthrop, 1979:(Sanofi internal report 105602-0010)

London diabetes, 1983:

unpublished

Oakley NW, Dormandy JA, Flute PT. Guildford: Sanofi Winthrop, 1983:(Internal report 105602-0019.)

TIMAD, 1984:

Mirouze J Agents Actions 1984;15(suppl):230-58

BTRS, 1992:

Ophthalmologica 1992;204:4-12 [[1579337](#)]

Nyberg, 1984:

Nyberg G, Larsson O, Westberg NG, Aurell M, Jagenburg R, Blohm G Clin Nephrol 1984;21:184-7 [[6705280](#)]

7 stent

Trial	Treatments	Patients	Trials design and methods
ticlopidine + aspirin vs aspirin			
STARS (vs aspirin) , 1998 n=546/557 follow-up:	Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj versus Aspirin 325 mg qD	-	
Hall , 1996 n=13/103	Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days versus Aspirin 325 mg qD	-	
ticlopidine + aspirin vs coumadin + aspirin			
STARS (vs coumadin+asp) , 1998 n=546/550 follow-up:	Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD versus Coumadin INR 22.5 x4 wks Aspirin 325 mg qDBID	-	
FANTASTIC , 1998 n=243/230	Ticlopidine 250 mg BID 6 wks Aspirin 100325 mg qD versus Coumadin INR 2.53.0 6 wks Aspirin 100325 mg qD/pj	-	
ISAR , 1996 n=257/260 follow-up:	Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj versus Coumadin INR 3.54.5 4 wks Aspirin 100 mg BID	-	
MATTIS , 1998 n=177/173	Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD versus Coumadin INR 2.53.0 x30 days Aspirin 250 mg qDg qD/pj	-	
Foussas , 2000 n=203/201	Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD versus Coumadin INR 23 x4 wks Aspirin 325 mg qDg BID	-	

More details and results :

- antithrombotics for stent in all type of patients at <http://www.trialresultscenter.org/go-Q151>

References

STARS (vs aspirin), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71 [9834303]

Hall, 1996:

Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-22 [8548891]

STARS (vs coumadin+asp), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71 [9834303]

FANTASTIC, 1998:

Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98:1597-603 [9778323]

ISAR, 1996:

Schmig A, Neumann FJ, Kastrati A, Schhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9 [8598866]

MATTIS, 1998:

Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-32 [9815866]

Foussas, 2000:

Foussas S, Alexopoulos D, Stefanadis C, Olympios C, Voudris V, Hatzimiltiadis S, Sionis D, Vavouranakis E, Vrahatis A, Fakiolas C, Pissimisis E, Stefanidis A, Zairis M, Pavlides G, Vitakis S, Louridas G, Cokkinos D, Toutouzas P Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. Angiology 2000;51:289-94 [10778998]

8 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
Berglund , 1985 n=21/17 follow-up: 2m	ticlopidine 500 mg daily versus placebo	middle-aged men with stable incapacitating angina pectoris	parallel groups double blind

More details and results :

- death and events prevention for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q450>

References

Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [[3911481](#)]

9 CABG surgery

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs control			
Zurich , 1982 n=50/50 follow-up: 3m	-	-	
Knudsen-B , 1983 n=9/10 follow-up: 6m	-	-	
Romeo , 1983 n=20/20 follow-up: 3m (12m)	-	-	
Kohn , 1990 n=21/24 follow-up: 14d	-	-	
ticlopidine vs placebo			
Lige-I , 1984 n=75/75 follow-up: 3m	ticlopidine 250 mg twice daily versus placebo	patients undergoing aortocoronary bypass graft procedures	double blind
Lige-II , 1987 n=88/87 follow-up: 12m	ticlopidine 250 mg twice daily versus placebo	patients undergoing venous coronary artery bypass grafting	double blind

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

References

Zurich, 1982:

Rothlin ME, Pflger K, Speiser K, Geroulanos SJ, Goebel N, Turina M, et al4 Clinical experience with anti-platelet drugs in aorta-coronary bypass surgery Coronary Artery Disease Today 1982;557:413-9

Knudsen-B, 1983:

Mortensen SA, Knudsen JB, Hjelms E, Efsen F. Pre- and post-operative platelet inhibition with ticlopidine in connexion with coronary artery bypass surgery (CABG).r=n Eur Heart J 1983;4 (suppl 3):Abstract 001 F.

Romeo, 1983:

Romeo F, Ruvolo G, Martuscelli E, Comito M, Cardona N, Colistra C, et al.gery Ticlopidine in the prevention of the block of aorto-coronary by-passP Proceedings of satellite symposium of 83rd Congress of Italian society of Internal Medicine. Rome: 1982:155-60

Kohn, 1990:

Kohn RN. Study of the safety of perioperative administration of ticlopidine hydrochloride in coronary artery bypass surgery.eur=n Guildford: Sanofi Winthrop, 1990 (Sanofi internal report 001.6.186)

Lige-I, 1984:

Chevign M, David JL, Rigo P, Limet R Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg 1984;37:371-8 [6608929]

Lige-II, 1987:

Limet R, David JL, Magotteaux P, Larock MP, Rigo P Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773-83 [3312825]

10 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs contrle			
Bequemín , 1997 n=122/121 follow-up: 24 mois	Ticlopidine (Ticlid, sanofi) 250 mg*2 /j versus placebo	Patients au stade II IV	Parallel groups Double aveugle
ticlopidine vs placebo			
Ellis , 1986 n=100/103 follow-up: 6 months	Ticlopidine 500 mg/j versus Placebo	AOMI stade II	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
Hurlow , 1980 n=30/30 follow-up:	Ticlopidine : 100 -500 mg / jour pendant 2 mois. versus Placebo	Donnes non disponibles	Parallel groups double blind
Krause , 1980 n=19/19 follow-up:	Ticlopidine : 500 mg pendant 4 mois versus Placebo	Donnes non disponibles	Parallel groups double blind
Katsumara , 1982 n=93/100 follow-up: 6 semaines	Ticlopidine 500 mg/j versus Placebo	patients with ischemic ulcers due to chronic arterial occlusion	Parallel groups double blind
Aukland , 1982 n=33/32 follow-up: 1 y	Ticlopidine 500 mg/j versus Placebo	men with atherosclerotic intermittent claudication and haemorheological abnormalities	Parallel groups double blind
Stiegler , 1984 n=57/57 follow-up:	Ticlopidine 500 mg/j versus Placebo	AOMI stade II	Parallel groups double blind
Cloarec , 1986 n=66/66 follow-up: 1 y	Ticlopidine 500 mg/j versus Placebo	AOMI stade non precis	Parallel groups double blind
Arcan , 1988 n=83/86 follow-up: 6 months	Ticlopidine 500 mg/j versus Placebo	patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II)	Parallel groups double blind
Balsano , 1989 n=76/75 follow-up: 21 months	Ticlopidine 500 mg/j versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
STIMS , 1990 n=346/341 follow-up: 5.6 y	Ticlopidine 500 mg/j versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
EMATAP , 1993 n=304/311 follow-up:	Ticlopidine 500 mg/j versus Placebo	AOMI stade non precis	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>
- antithrombotics for peripheral vascular diseases in after revascularisation at <http://www.trialresultscenter.org/go-Q661>

References

Becquemin, 1997:

Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. Becquemin JP N Engl J Med 1997 Dec 11;337:1726-31 [[9392698](#)]

Ellis, 1986:

DJ Ellis, BR Kamm. Treatment of intermittent claudication with Ticlopidine. Institute of Clinical Medicine, Syntex Research. Palo Alto.CA 94304, USA. Modifier — Effacer — pdf

Hurlow, 1980:

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

Krause, 1980:

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

Katsumara, 1982:

Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A Angiology 1982 Jun;33:357-67 [[7046521](#)]

Aukland, 1982:

Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. Aukland A, Hurlow RA, George AJ, Stuart J J Clin Pathol 1982 Jul;35:740-3 [[7047575](#)]

Stiegler, 1984:

H Stiegler, H Hess, A Mietaschk, H-J, Trampisch and Ingrisich. DMW 1984, 109:1240-1243.

Cloarec, 1986:

Cloarec M et al Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs Thrombosis Research 1986 suppl VI abstr 316

Arcan, 1988:

Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E Angiology 1988 Sep;39:802-11 [[3048155](#)]

Balsano, 1989:

Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P J Lab Clin Med 1989 Jul;114:84-91 [[2661700](#)]

STIMS, 1990:

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al J Intern Med 1990 May;227:301-8 [[2187948](#)]

EMATAP, 1993:

J Blanchard, LO Carrerars, M Kindermans and the EMATAP group. Results of EMATAP: a dooble-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev fr Hematol(1993)35:523-528.

11 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs placebo			
TACT , 1990 n=177/173 follow-up: 6m	-	-	Parallel groups
White (ticlopidine) , 1991 n=NA follow-up: 6m	ticlopidine 500, aspirin 650 + D225 versus placebo	-	Parallel groups
ticlopidine + aspirin vs aspirin			
STARS (vs aspirin) , 1998 n=546/557 follow-up:	Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj versus Aspirin 325 mg qD	-	
Hall , 1996 n=13/103	Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days versus Aspirin 325 mg qD	-	
ticlopidine + aspirin vs coumadin + aspirin			
STARS (vs coumadin+asp) , 1998 n=546/550 follow-up:	Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD versus Coumadin INR 22.5 x4 wks Aspirin 325 mg qDBID	-	
FANTASTIC , 1998 n=243/230	Ticlopidine 250 mg BID 6 wks Aspirin 100325 mg qD versus Coumadin INR 2.53.0 6 wks Aspirin 100325 mg qD/pj	-	
ISAR , 1996 n=257/260 follow-up:	Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj versus Coumadin INR 3.54.5 4 wks Aspirin 100 mg BID	-	
MATTIS , 1998 n=177/173	Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD versus Coumadin INR 2.53.0 x30 days Aspirin 250 mg qDg qD/pj	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Foussas , 2000 n=203/201	Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD versus Coumadin INR 23 x4 wks Aspirin 325 mg qDg BID	-	

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- antithrombotics for percutaneous coronary intervention in PCI with stent placement at <http://www.trialresultscenter.org/go-Q152>
- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>

References

TACT, 1990:

Bertrand ME, Allain H, LaBlanche JM, on behalf of Investigators of the TACT Study Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study *Circulation* 1990;82(suppl III):190 (Abstract 0754)

White (ticlopidine), 1991:

STARS (vs aspirin), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med* 1998;339:1665-71 [9834303]

Hall, 1996:

Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. *Circulation* 1996;93:215-22 [8548891]

STARS (vs coumadin+asp), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med* 1998;339:1665-71 [9834303]

FANTASTIC, 1998:

Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. *Circulation* 1998;98:1597-603 [9778323]

ISAR, 1996:

Schmig A, Neumann FJ, Kastrati A, Schhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;334:1084-9 [8598866]

MATTIS, 1998:

Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). *Circulation* 1998;98:2126-32 [[9815866](#)]

Foussas, 2000:

Foussas S, Alexopoulos D, Stefanadis C, Olympios C, Voudris V, Hatzimiltiadis S, Sionis D, Vavouranakis E, Vrahatis A, Fakiolas C, Pissimisis E, Stefanidis A, Zairis M, Pavlides G, Vitakis S, Louridas G, Cokkinos D, Toutouzas P Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. *Angiology* 2000;51:289-94 [[10778998](#)]

Entry terms: Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodone, 53-32C, 53 32C, 5332C, Ticlid,